Bristol Myers Squibb (BMY) Current Deferred Revenue (2009 - 2026)

Bristol Myers Squibb has disclosed Current Deferred Revenue across 18 years of filings, most recently posting $168.0 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 22.58% year-over-year to $168.0 million; the TTM figure through Mar 2026 stood at $168.0 million (down 22.58% YoY), while the FY2025 annual figure was $175.0 million, up 27.74% from the prior year.
• Current Deferred Revenue slipped to $168.0 million in Q1 2026, from $175.0 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for BMY reached as high as $326.0 million in Q1 2022 and fell as low as $137.0 million in Q4 2024.
• The 5-year median for Current Deferred Revenue is $263.0 million (2024), against an average of $250.2 million.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue slumped 50.0% — and 2025, when it gained 27.74%.
• A 5-year view of Current Deferred Revenue shows it stood at $289.0 million in 2022, then fell by 5.19% to $274.0 million in 2023, then tumbled by 50.0% to $137.0 million in 2024, then climbed by 27.74% to $175.0 million in 2025, then declined by 4.0% to $168.0 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $168.0 million, $175.0 million, and $190.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.